Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:CRDF NASDAQ:FATE NASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.12-0.3%$15.01$12.96▼$20.90$317.05M0.880,523 shs57,127 shsCRDFCardiff Oncology$1.32+5.6%$1.52$1.16▼$4.56$90.25M1.441.14 million shs956,346 shsFATEFate Therapeutics$3.11+6.1%$2.20$0.91▼$3.21$362.50M2.512.71 million shs3.05 million shsINDPIndaptus Therapeutics$2.50+2.0%$2.55$0.92▼$13.40$283.10M1.11522,362 shs54,646 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-1.88%-7.89%+6.83%+2.64%-9.86%CRDFCardiff Oncology-7.41%-3.10%-16.67%-25.15%-68.27%FATEFate Therapeutics-2.98%-2.98%+53.40%+130.71%+168.81%INDPIndaptus Therapeutics-8.24%-16.67%+16.67%+32.43%-79.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.12-0.3%$15.01$12.96▼$20.90$317.05M0.880,523 shs57,127 shsCRDFCardiff Oncology$1.32+5.6%$1.52$1.16▼$4.56$90.25M1.441.14 million shs956,346 shsFATEFate Therapeutics$3.11+6.1%$2.20$0.91▼$3.21$362.50M2.512.71 million shs3.05 million shsINDPIndaptus Therapeutics$2.50+2.0%$2.55$0.92▼$13.40$283.10M1.11522,362 shs54,646 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-1.88%-7.89%+6.83%+2.64%-9.86%CRDFCardiff Oncology-7.41%-3.10%-16.67%-25.15%-68.27%FATEFate Therapeutics-2.98%-2.98%+53.40%+130.71%+168.81%INDPIndaptus Therapeutics-8.24%-16.67%+16.67%+32.43%-79.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.50Moderate BuyN/AN/ACRDFCardiff Oncology 2.17Hold$7.50468.18% UpsideFATEFate Therapeutics 2.29Hold$5.1364.79% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CRDF, AMRN, INDP, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/8/2026FATEFate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/3/2026CRDFCardiff Oncology Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$2.006/1/2026CRDFCardiff Oncology TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/1/2026CRDFCardiff Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/18/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/18/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026FATEFate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026FATEFate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $7.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$216.76M1.46$0.35 per share42.83$22.07 per share0.69CRDFCardiff Oncology$525K171.90N/AN/A$0.67 per share1.97FATEFate Therapeutics$6.65M54.51N/AN/A$1.80 per share1.73INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)CRDFCardiff Oncology-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)FATEFate Therapeutics-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)Latest CRDF, AMRN, INDP, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026CRDFCardiff Oncology-$0.17N/AN/AN/A$0.06 millionN/A7/29/2026Q2 2026AMRNAmarin-$0.09N/AN/AN/A$44.55 millionN/A5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million5/13/2026Q1 2026FATEFate Therapeutics-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46CRDFCardiff OncologyN/A3.273.27FATEFate TherapeuticsN/A5.855.85INDPIndaptus TherapeuticsN/A2.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%CRDFCardiff Oncology16.29%FATEFate Therapeutics97.54%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%CRDFCardiff Oncology8.50%FATEFate Therapeutics4.74%INDPIndaptus Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.97 million20.09 millionOptionableCRDFCardiff Oncology2068.37 million62.56 millionOptionableFATEFate Therapeutics550116.56 million111.03 millionOptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableCRDF, AMRN, INDP, and FATE HeadlinesRecent News About These CompaniesIndaptus Therapeutics Announces Private Placement of Common StockJune 24, 2026 | tipranks.comAbbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. StockholdersJune 17, 2026 | globenewswire.comIndaptus Therapeutics Announces Recent Board and Leadership ChangesJune 5, 2026 | tipranks.comIndaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertaintyJune 4, 2026 | quiverquant.comQIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comIndaptus Therapeutics Adds Independent Directors Amid Board RefreshApril 23, 2026 | tipranks.comIndaptus Therapeutics Appoints David Natan to BoardJanuary 8, 2026 | tipranks.comBiolojic Design appoints new chief medical officerJanuary 8, 2026 | thepharmaletter.comTIndaptus Therapeutics announces upcoming board leadership transitionJanuary 3, 2026 | msn.comIndaptus Therapeutics enters $6M securities purchase agreement with David LazarDecember 29, 2025 | msn.comIndaptus Therapeutics stock falls after $6 million securities dealDecember 29, 2025 | za.investing.comWhy did INDP stock gain 12% today?December 29, 2025 | msn.comIndaptus Therapeutics Secures $6 Million Investment from David E. Lazar, Appoints Him Co-CEO and ChairmanDecember 29, 2025 | quiverquant.comQIndaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarDecember 29, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 60.00% to 10.20November 17, 2025 | msn.comIndaptus Therapeutics to Present Advances in Allogeneic Immune Cell Therapy at 3rd Donor Selection & Cell Source SummitNovember 17, 2025 | quiverquant.comQIndaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source SummitNovember 17, 2025 | globenewswire.comIndaptus Therapeutics Reports Q3 2025 Financial Results and Corporate UpdateNovember 12, 2025 | quiverquant.comQIndaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNovember 12, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 86.15% to 25.50October 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDF, AMRN, INDP, and FATE Company DescriptionsAmarin NASDAQ:AMRN$15.12 -0.05 (-0.33%) Closing price 04:00 PM EasternExtended Trading$15.11 -0.01 (-0.07%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Cardiff Oncology NASDAQ:CRDF$1.32 +0.07 (+5.60%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Fate Therapeutics NASDAQ:FATE$3.11 +0.18 (+6.14%) Closing price 04:00 PM EasternExtended Trading$3.15 +0.04 (+1.16%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Indaptus Therapeutics NASDAQ:INDP$2.50 +0.05 (+2.04%) Closing price 04:00 PM EasternExtended Trading$2.50 0.00 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
